person · Reporting owner

WIGGANS THOMAS G

Disclosed activity across 7 companies

Tapewire entity: 26600
SEC CIK: 0001208907

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Annexon, Inc.ANNX · Entity 5011	Director	June 05, 2025	June 09, 2025
Jasper Therapeutics, Inc.JSPR · Entity 7588	Director	July 31, 2026	August 04, 2026
Pacira BioSciences, Inc.PCRX · Entity 4928	Director	June 10, 2026	June 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Annexon, Inc.

Report date June 05, 2025 · Filed June 09, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2035-06-05	Direct	55,000	Reported balance After 2025-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-05 · Grant · Acquired 55,000 · Balance 55,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date.

Jasper Therapeutics, Inc.

Report date July 31, 2026 · Filed August 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2036-07-31	Direct	7,500	Reported balance After 2026-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-31 · Grant · Acquired 7,500 · Balance 7,500 F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.

Pacira BioSciences, Inc.

Report date June 10, 2026 · Filed June 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10	Direct	32,675	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 32,675 · Balance 32,675 F1: The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CymaBay Therapeutics, Inc.

Report date March 22, 2024 · Filed March 22, 2024

Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63 · Expires 2031-04-04	Direct	Reported balance After 2024-03-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-03-22 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2032-01-24	Direct	Reported balance After 2024-03-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-03-22 · Disposition to issuer · Disposed 67,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24	Direct	Reported balance After 2024-03-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23	Direct	Reported balance After 2024-03-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-03-22 · Disposition to issuer · Disposed 14,010 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

Dermira, Inc.

Report date February 20, 2020 · Filed February 25, 2020

Section 16 reporting ended · disclosed 2020-02-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	49,963	Reported balance After 2020-02-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-02-05 · Gift · Disposed 27,000 · Balance 49,963 F1: Includes 1,023 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-02-20 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2020-02-20 · Disposition to issuer · Disposed 49,963 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Common StockSEC Table I · non-derivative	IndirectBy the Wiggans Living Trust dated 5/14/02	0	Reported balance After 2020-02-20 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-02-20 · Disposition to issuer · Disposed 180,985 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: The Reporting Person is a Co-Trustee.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2021-10-03	Direct	0	Reported balance After 2020-02-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-02-20 · Disposition to issuer · Disposed 164,642 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2023-01-03	Direct	0	Reported balance After 2020-02-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-02-20 · Disposition to issuer · Disposed 115,022 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2023-01-03	Direct	0	Reported balance After 2020-02-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-02-20 · Disposition to issuer · Disposed 64,327 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-10-01	Direct	0	Reported balance After 2020-02-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-02-20 · Disposition to issuer · Disposed 355,170 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.37 · Expires 2026-02-04	Direct	0	Reported balance After 2020-02-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-02-20 · Disposition to issuer · Disposed 180,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2023-07-10	Direct	0	Reported balance After 2020-02-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-02-20 · Disposition to issuer · Disposed 98,430 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2027-02-16	Direct	0	Reported balance After 2020-02-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-02-20 · Disposition to issuer · Disposed 180,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.25 · Expires 2028-02-14	Direct	0	Reported balance After 2020-02-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-02-20 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.42 · Expires 2029-02-11	Direct	0	Reported balance After 2020-02-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-02-20 · Disposition to issuer · Disposed 300,000 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-02-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2020-02-20 · Disposition to issuer · Disposed 9,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-02-20 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2020-02-20 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-02-20 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2020-02-20 · Disposition to issuer · Disposed 50,000 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 1,023 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan.

F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F3: The Reporting Person is a Co-Trustee.

F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

Forma Therapeutics Holdings, Inc.

Report date October 14, 2022 · Filed October 14, 2022

Section 16 reporting ended · disclosed 2022-10-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-14 transaction · row 1 1 source row Row 1 · 2022-10-14 · Other · Disposed 7,250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.50	Direct	Reported balance After 2022-10-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-14 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.35	Direct	Reported balance After 2022-10-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-14 · Disposition to issuer · Disposed 8,375 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12	Direct	Reported balance After 2022-10-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-14 · Disposition to issuer · Disposed 6,750 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

PARDES BIOSCIENCES, INC.

Report date August 31, 2023 · Filed August 31, 2023

Section 16 reporting ended · disclosed 2023-08-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-08-31 transaction · row 1 1 source row Row 1 · 2023-08-31 · Other · Disposed 50,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2033-01-31	Direct	Reported balance After 2023-08-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-08-31 · Disposition to issuer · Disposed 562,500 · Balance 0 F3: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2032-03-01	Direct	Reported balance After 2023-08-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-08-31 · Disposition to issuer · Disposed 985,000 · Balance 0 F4: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.98 · Expires 2032-09-13	Direct	Reported balance After 2023-08-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-08-31 · Disposition to issuer · Disposed 450,000 · Balance 0 F4: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time).

F2: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right.

F3: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto.

F4: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 31, 2026 Filed Aug 4, 2026 20:11 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	GrantStock Option (Right to Buy · Derivative	7,500	$0.00 Strike: $0.63	$0.00	Disclosure SEC source: 0001213900-26-085192 · ownership.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2036-07-31 F1 · derivative.exercise_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. F1 · derivative.expiration_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	32,675	$0.00 Strike: $23.42	$0.00	Disclosure SEC source: 0001628280-26-043007 · wk-form4_1781312848.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,675 Underlying: Common Stock · 32,675 shares Expires 2036-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document
September 22, 2025 Filed Sep 24, 2025 20:01 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseCommon Stock Warrant (right to buy) · Derivative	41,000	Not disclosed Strike: $2.92	Not disclosed	Disclosure SEC source: 0001213900-25-091105 · ownership.xml · derivative · entry 3 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Wiggans Living Trust Disclosed balance after: 41,000 Underlying: Voting Common Stock · 41,000 shares Expires 2030-03-22 F1 · price: Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant. Read SEC document
September 22, 2025 Filed Sep 24, 2025 20:01 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseVoting Common Stock	41,000	$2.43	$99,630.00	Disclosure SEC source: 0001213900-25-091105 · ownership.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Wiggans Living Trust Disclosed balance after: 41,000 F1 · price: Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant. Read SEC document
July 03, 2025 Filed Jul 3, 2025 20:21 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	GrantStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $6.77	$0.00	Disclosure SEC source: 0001213900-25-061493 · ownership.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2035-07-03 F1 · shares: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders. Read SEC document
June 05, 2025 Filed Jun 9, 2025 20:30 UTC	Annexon, Inc. ANNX · Entity 5011	GrantStock Option (Right to Buy) · Derivative	55,000	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001415889-25-016275 · form4-06092025_080622.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document
June 06, 2024 Filed Jun 10, 2024 22:20 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	GrantStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $25.41	$0.00	Disclosure SEC source: 0001213900-24-051405 · ownership.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2034-06-06 Read SEC document
June 05, 2024 Filed Jun 8, 2024 01:45 UTC	Annexon, Inc. ANNX · Entity 5011	GrantStock Option (Right to Buy) · Derivative	44,000	$0.00 Strike: $6.79	$0.00	Disclosure SEC source: 0001415889-24-016111 · form4-06082024_010649.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2024 or (ii) the next Annual Meeting following June 5, 2024, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:54 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	14,010	Not disclosed Strike: $22.85	Not disclosed	Disclosure SEC source: 0000950170-24-035446 · ownership.xml · derivative · entry 4 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,010 shares Expires 2034-01-23 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:54 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	25,000	Not disclosed Strike: $7.80	Not disclosed	Disclosure SEC source: 0000950170-24-035446 · ownership.xml · derivative · entry 3 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2033-01-24 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:54 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	67,000	Not disclosed Strike: $2.94	Not disclosed	Disclosure SEC source: 0000950170-24-035446 · ownership.xml · derivative · entry 2 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,000 shares Expires 2032-01-24 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
March 22, 2024 Filed Mar 22, 2024 16:54 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	80,000	Not disclosed Strike: $4.63	Not disclosed	Disclosure SEC source: 0000950170-24-035446 · ownership.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2031-04-04 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration. Read SEC document
January 24, 2024 Filed Jan 26, 2024 18:18 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	14,010	$0.00 Strike: $22.85	$0.00	Disclosure SEC source: 0001062993-24-001420 · form4.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,010 Underlying: Common Stock · 14,010 shares Expires 2034-01-23 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2024. Read SEC document
November 28, 2023 Filed Nov 30, 2023 21:05 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseVoting Common Stock	10,000	$0.65	$6,486.00	Disclosure SEC source: 0001213900-23-091458 · ownership.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6311 to $0.669, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document
November 21, 2023 Filed Nov 22, 2023 21:06 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseVoting Common Stock	10,000	$0.64	$6,383.00	Disclosure SEC source: 0001213900-23-089579 · ownership.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63 to $0.65, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document
November 20, 2023 Filed Nov 21, 2023 01:14 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseVoting Common Stock	10,000	$0.63	$6,309.00	Disclosure SEC source: 0001213900-23-088896 · ownership.xml · nonDerivative · entry 3 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.616 to $0.64, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document
November 17, 2023 Filed Nov 21, 2023 01:14 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseVoting Common Stock	10,000	$0.60	$5,966.00	Disclosure SEC source: 0001213900-23-088896 · ownership.xml · nonDerivative · entry 2 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5889 to $0.60, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price. Read SEC document
November 16, 2023 Filed Nov 21, 2023 01:14 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	PurchaseVoting Common Stock	10,000	$0.60	$5,965.00	Disclosure SEC source: 0001213900-23-088896 · ownership.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document
November 01, 2023 Filed Nov 2, 2023 22:00 UTC	Jasper Therapeutics, Inc. JSPR · Entity 7588	GrantStock Option (right to buy) · Derivative	110,000	$0.00 Strike: $0.69	$0.00	Disclosure SEC source: 0001213900-23-082883 · ownership.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Voting Common Stock · 110,000 shares Expires 2033-11-01 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on November 1, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document
August 31, 2023 Filed Aug 31, 2023 18:55 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	Disposition to issuerStock Option (Right to Buy) · Derivative	450,000	Not disclosed Strike: $2.98	Not disclosed	Disclosure SEC source: 0001209191-23-047836 · doc4.xml · derivative · entry 4 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2032-09-13 F4 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document
August 31, 2023 Filed Aug 31, 2023 18:55 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	Disposition to issuerStock Option (Right to Buy) · Derivative	985,000	Not disclosed Strike: $6.36	Not disclosed	Disclosure SEC source: 0001209191-23-047836 · doc4.xml · derivative · entry 3 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 985,000 shares Expires 2032-03-01 F4 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. F4 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time. Read SEC document
August 31, 2023 Filed Aug 31, 2023 18:55 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	Disposition to issuerStock Option (Right to Buy) · Derivative	562,500	Not disclosed Strike: $2.08	Not disclosed	Disclosure SEC source: 0001209191-23-047836 · doc4.xml · derivative · entry 2 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 562,500 shares Expires 2033-01-31 F3 · price: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F3 · derivative.exercise_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. F3 · derivative.expiration_date: On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto. Read SEC document
August 31, 2023 Filed Aug 31, 2023 18:55 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	OtherCommon Stock	50,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-047836 · doc4.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time). F2 · price: Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right. Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:50 UTC	Annexon, Inc. ANNX · Entity 5011	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $2.88	$0.00	Disclosure SEC source: 0001610717-23-000144 · form4.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 8, 2023 or (ii) the next Annual Meeting following June 8, 2023, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document
February 01, 2023 Filed Feb 3, 2023 21:36 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	GrantStock Option (Right to Buy) · Derivative	562,500	$0.00 Strike: $2.08	$0.00	Disclosure SEC source: 0001209191-23-006896 · doc4.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,500 Underlying: Common Stock · 562,500 shares Expires 2033-02-01 F1 · derivative.exercise_date: Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the 1st day of each month after the Grant Date (02/01/2023), subject to continued service relationship. Read SEC document
January 25, 2023 Filed Jan 27, 2023 16:34 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $7.80	$0.00	Disclosure SEC source: 0001062993-23-001498 · form4.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-01-24 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2023. Read SEC document
December 05, 2022 Filed Dec 7, 2022 21:29 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	PurchaseCommon Stock	12,500	$1.09	$13,625.00	Disclosure SEC source: 0001209191-22-060154 · doc4.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price in Column 4 is a weighted average price. The prices actually paid ranged from $1.02 to $1.20. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
December 02, 2022 Filed Dec 5, 2022 21:21 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	PurchaseCommon Stock	12,500	$1.07	$13,375.00	Disclosure SEC source: 0001209191-22-059677 · doc4.xml · nonDerivative · entry 2 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 F2 · price: The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. F3 · price: The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $1.02 to $1.12. Read SEC document
December 01, 2022 Filed Dec 5, 2022 21:21 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	PurchaseCommon Stock	25,000	$1.04	$26,000.00	Disclosure SEC source: 0001209191-22-059677 · doc4.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · price: The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $0.96025 to $1.05. F2 · price: The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range. Read SEC document
October 14, 2022 Filed Oct 14, 2022 20:06 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	Disposition to issuerStock Option (Right to Buy) · Derivative	6,750	Not disclosed Strike: $6.12	Not disclosed	Disclosure SEC source: 0000899243-22-033650 · doc4.xml · derivative · entry 4 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,750 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document
October 14, 2022 Filed Oct 14, 2022 20:06 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	Disposition to issuerStock Option (Right to Buy) · Derivative	8,375	Not disclosed Strike: $25.35	Not disclosed	Disclosure SEC source: 0000899243-22-033650 · doc4.xml · derivative · entry 3 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,375 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document
October 14, 2022 Filed Oct 14, 2022 20:06 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	Not disclosed Strike: $39.50	Not disclosed	Disclosure SEC source: 0000899243-22-033650 · doc4.xml · derivative · entry 2 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document
October 14, 2022 Filed Oct 14, 2022 20:06 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	OtherCommon Stock	7,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033650 · doc4.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2 · kind: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · shares: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · price: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. Read SEC document
September 14, 2022 Filed Sep 16, 2022 20:17 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	GrantStock Option (Right to Buy) · Derivative	450,000	$0.00 Strike: $2.98	$0.00	Disclosure SEC source: 0001209191-22-050318 · doc4.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2032-09-14 F1 · derivative.exercise_date: 1/2 of the shares subject to such option vest and become exercisable on September 14, 2023, and 1/24th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on the 14th day of each month thereafter, subject to continued service relationship. Options vest over two years with 1/2 of the shares subject to such option vesting and becoming exercisable on September 14, 2023, and the remaining 1/2 of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the 14th day of each month thereafter, subject to continued service relationship. Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:44 UTC	Annexon, Inc. ANNX · Entity 5011	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $3.84	$0.00	Disclosure SEC source: 0001567619-22-012781 · doc1.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 9, 2022 or (ii) the next Annual Meeting following June 9, 2022, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document
June 08, 2022 Filed Jun 9, 2022 21:34 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	GrantStock Option (Right to Buy) · Derivative	6,750	$0.00 Strike: $6.12	$0.00	Disclosure SEC source: 0000899243-22-021666 · doc4.xml · derivative · entry 2 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 6,750 shares Expires 2032-06-07 F2 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 8, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
June 08, 2022 Filed Jun 9, 2022 21:34 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0000899243-22-021666 · doc4.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document
March 02, 2022 Filed Mar 4, 2022 21:40 UTC	PARDES BIOSCIENCES, INC. PRDS · Entity 110063	GrantStock Option (Right to Buy) · Derivative	985,000	$0.00 Strike: $6.36	$0.00	Disclosure SEC source: 0000899243-22-009403 · doc4.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 985,000 Underlying: Common Stock · 985,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: 1/4th of the shares subject to such option vest and become exercisable on the first anniversary of March 1, 2022 and the remaining 3/4th of the shares subject to such option will vest and become exercisable in substantially equal monthly installments on the 1st day of each month thereafter, subject to a continued service relationship. Read SEC document
January 25, 2022 Filed Jan 27, 2022 16:54 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	67,000	$0.00 Strike: $2.94	$0.00	Disclosure SEC source: 0001062993-22-001696 · form4.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2032-01-24 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2022. Read SEC document
June 17, 2021 Filed Jun 21, 2021 23:05 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	GrantStock Option (Right to Buy) · Derivative	8,375	$0.00 Strike: $25.35	$0.00	Disclosure SEC source: 0000899243-21-025095 · doc4.xml · derivative · entry 2 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,375 Underlying: Common Stock · 8,375 shares Expires 2031-06-16 F2 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 17, 2022 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
June 17, 2021 Filed Jun 21, 2021 23:05 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	GrantCommon Stock	2,750	$0.00	$0.00	Disclosure SEC source: 0000899243-21-025095 · doc4.xml · nonDerivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 F1 · shares: These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document
June 02, 2021 Filed Jun 4, 2021 21:12 UTC	Annexon, Inc. ANNX · Entity 5011	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $21.03	$0.00	Disclosure SEC source: 0001567619-21-011722 · doc1.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 2, 2021 or (ii) the next Annual Meeting following June 2, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document
April 05, 2021 Filed Apr 5, 2021 17:01 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	80,000	$0.00 Strike: $4.63	$0.00	Disclosure SEC source: 0001333277-21-000036 · edgar.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-04-04 F1 · derivative.exercise_date: The option vests as to 1/36 of the underlying shares monthly from April 5, 2021. Read SEC document
September 07, 2020 Filed Sep 9, 2020 20:05 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	GrantStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $39.50	$0.00	Disclosure SEC source: 0000899243-20-024633 · doc4.xml · derivative · entry 1 WIGGANS THOMAS G · CIK 0001208907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-09-06 F1 · derivative.exercise_date: 33.3% of the shares subject to the stock option shall vest on September 7, 2021; and the remainder of the shares shall vest in equal monthly installments for a period of 24 months thereafter, subject to continued service with the Issuer. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerRestricted Stock Unit · Derivative	50,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-001616 · primarydocument.xml · derivative · entry 15 WIGGANS THOMAS G · CIK 0001208907 · Director · CEO & Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed F5 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F2 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerRestricted Stock Unit · Derivative	15,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-001616 · primarydocument.xml · derivative · entry 14 WIGGANS THOMAS G · CIK 0001208907 · Director · CEO & Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerRestricted Stock Unit · Derivative	9,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-001616 · primarydocument.xml · derivative · entry 13 WIGGANS THOMAS G · CIK 0001208907 · Director · CEO & Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerEmployee Stock Options (Right to buy) · Derivative	300,000	Not disclosed Strike: $7.42	Not disclosed	Disclosure SEC source: 0001562180-20-001616 · primarydocument.xml · derivative · entry 12 WIGGANS THOMAS G · CIK 0001208907 · Director · CEO & Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2029-02-11 F2 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerEmployee Stock Options (Right to buy) · Derivative	150,000	Not disclosed Strike: $28.25	Not disclosed	Disclosure SEC source: 0001562180-20-001616 · primarydocument.xml · derivative · entry 11 WIGGANS THOMAS G · CIK 0001208907 · Director · CEO & Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2028-02-14 F2 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:31 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerEmployee Stock Options (Right to buy) · Derivative	180,000	Not disclosed Strike: $33.84	Not disclosed	Disclosure SEC source: 0001562180-20-001616 · primarydocument.xml · derivative · entry 10 WIGGANS THOMAS G · CIK 0001208907 · Director · CEO & Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 180,000 shares Expires 2027-02-16 F2 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.